Author Archives: admin


The PRP Alternative to Knee and Other Surgeries – Sahuarita Sun

Last month we talked about using hyaluronic acid (HA) injections as an alternative to knee replacement surgery. Another alternative to knee replacement is platelet rich plasma, known simply as PRP.

PRP promotes natural healing.

Steroid injections have been one of the standard treatments used as an alternative to knee surgery. But steroids have limitations in how often they can be used, and may not work well for long-term results.

PRP uses the patients own blood components. After blood is drawn, it is placed into a centrifuge, which spins to isolate the platelets. The PRP is then injected into the affected area. The concentrated PRP promotes healing of the injured or inflamed area. Relief begins within a few weeks of the injection, and pain decreases even more as the healing continues.

In addition to being a viable alternative to knee surgery, PRP is effective for rotator cuff issues, pelvic pain and instability, tennis elbow, tendonitis, muscle strains and more.

Now at affordable prices.

Insurance may or may not cover PRP, but it is now affordable enough for most patients to pay for PRP on their own.

For more information, call Pima Orthopedics at 520-624-0888 and ask about the Non-Surgical Knee Relief Program at our Tucson and Green Valley offices.

See the original post:
The PRP Alternative to Knee and Other Surgeries - Sahuarita Sun

Platelet Rich Plasma Market: Applications, Business Trends by Size 2021: Growth Statistics and Key Players Insights by Types, and Development Analysis…

The rising prevalence of the arthritis is augmenting the demand of the blood products, which is ultimately helping the growth of the platelet-rich plasma market.

For More Information or Query or Customization Before Buying, Visit at https://www.industryresearch.co/enquiry/pre-order-enquiry/13999558

Key Market Trends:

Pure PRP Segment by Type is Expected to Hold the Largest Market Share

The pure PRP segment of the global platelet rich plasma market is believed to have the largest market share.

The prime factor responsible for the growth of this segment is the significance of this type of platelet plasma for the person. Pure PRP has an edge over traditional PRP, as it requires a two-step concentration process that helps in eliminating unwanted red blood cells (RBCs) and neutrophils. RBCs (that have no therapeutic effects for regeneration) can create a more viscous solution that can be more painful when injected. Neutrophils, a type of white blood cell, have inflammatory components that may increase pain and inflammation post-treatment.

Pure PRP helps the stem cells and regenerative cells in the repair and in rebuilding the damaged tissue. This ultimately speeds up the healing process and reduces pain. In addition, it promotes increased strength and improves the overall function. Therefore, owing to the contribution of pure PRP in the healing process and the rising use of it as a blood product, the segment is expected to dominate the market in the coming future.

North America Dominates the Market and is Expected to Continue the Same Trend for Next Few Years

North America currently dominates the platelet-rich plasma market and is expected to continue its stronghold for a few more years. The United States is a major market, and this is mainly due to the US governments initiatives to develop blood products. In addition, the emergence and adoption of novel technologies are going to help the market in a positive manner.

Reasons to Purchase this Report:

Purchase this Report (Price 4250 USD for single user license) https://www.industryresearch.co/purchase/13999558

Key questions answered in the report:

Detailed TOC of Platelet Rich Plasma Market Segmented by Geography Growth, Trend, and Forecast:

1 INTRODUCTION 1.1 Study Deliverables 1.2 Study Assumptions 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS 4.1 Market Overview 4.2 Market Drivers 4.2.1 Rising Incidences of Sports Injuries 4.2.2 Increasing Number of Androgenic Alopecia Patients 4.2.3 Growing Use of Platelet-rich Plasma in Various Therapeutic Areas 4.2.4 Rising Prevalence of Arthritis 4.3 Market Restraints 4.3.1 Stringent Regulatory Policies 4.3.2 High Prices of Plasma Therapy 4.4 Porters Five Forces Analysis 4.4.1 Threat of New Entrants 4.4.2 Bargaining Power of Buyers/Consumers 4.4.3 Bargaining Power of Suppliers 4.4.4 Threat of Substitute Products 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION 5.1 By Type 5.1.1 Pure PRP 5.1.2 Leukocyte-rich PRP 5.1.3 Pure Platelet-rich Fibrin 5.1.4 Leukocyte-rich Fibrin 5.2 By Source 5.2.1 Autologous 5.2.2 Allogenic 5.3 By Application 5.3.1 Orthopedic 5.3.1.1 Arthritis 5.3.1.2 Chronic Tendinitis 5.3.1.3 Bone Repair and Regeneration 5.3.2 Dermatology 5.3.2.1 Androgenic Alopecia 5.3.2.2 Plastic Surgery 5.3.2.3 Cardiac Muscle Injury 5.3.2.4 Dental 5.3.2.5 Nerve Injury 5.3.2.6 Other Applications 5.3.3 By End User 5.3.3.1 Hospitals and Clinics 5.3.3.2 Research Institutes 5.3.3.3 Other End Users 5.4 Geography 5.4.1 North America 5.4.1.1 United States 5.4.1.2 Canada 5.4.1.3 Mexico 5.4.2 Europe 5.4.2.1 Germany 5.4.2.2 United Kingdom 5.4.2.3 France 5.4.2.4 Italy 5.4.2.5 Spain 5.4.2.6 Rest of Europe 5.4.3 Asia-Pacific 5.4.3.1 China 5.4.3.2 Japan 5.4.3.3 India 5.4.3.4 Australia 5.4.3.5 South Korea 5.4.3.6 Rest of Asia-Pacific 5.4.4 Middle East & Africa 5.4.4.1 GCC 5.4.4.2 South Africa 5.4.4.3 Rest of Middle East & Africa 5.4.5 South America 5.4.5.1 Brazil 5.4.5.2 Argentina 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE 6.1 Company Profiles 6.1.1 Bio Product Laboratory Ltd (BPL) 6.1.2 Biolife Plasma Services 6.1.3 Biotest AG 6.1.4 Cambryn Biologics LLC 6.1.5 China Biologic Products Inc. 6.1.6 CSL Ltd 6.1.7 Grifols International SA 6.1.8 Kedrion SpA 6.1.9 LFB SA 6.1.10 Octapharma AG

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Contact Us:

Name: Ajay More

Phone: US +14242530807/ UK +44 20 3239 8187

Email: [emailprotected]

Our Other Reports:

Folding Box Board Market Size and Share Analysis 2020: with Covid-19 Impact on Global Business Growth, Forthcoming Developments Forecast to 2026 | Industry Research.co

Ultra-High Strength Steel Market Growth Rate and Business Share 2020: Global Industry Current Trends, Top Companies, Sales and Drivers Analysis Research Report to 2026 | Industry Research.co

Paper Processing Resins Market Share Value Analysis with Key Technologies 2021 Market Dynamics of Key Players, Global Opportunities, Demand Status Forecast till 2026

Lactose-free Milk Powders Market Size Report 2021: Covid-19 Impact Analysis with Top Key Players, Global Industry Share, Future Scope, Business Strategies and Demand Forecast to 2026

Data Center Power Market Share and Forecast Analysis 2021-2023 | Latest Developments of Industry, Segmentation, Global Growth Trends and Business Strategies with Covid-19 Impact

Brushless DC Motors Market Size Trends and Vendor Analysis 2021: includes Drivers and Challenges, Value Chain Analysis by Global Share, Scope and Growth Technology Forecast to 2024 Industry Research.co

Swimming Equipment Market- 2020 Growth and Business Prospects, Industry Size Forecast by Share, Revenue, Development Status, Demand by Regions, Market Potentials Analysis till 2026

Laminated Reel Labels Market Share and Size Analysis 2020 Global Industry Segments by Regions, Types and Applications, Future Demand Status, Growth Dynamics with COVID-19 Impact till 2026

Car Leasing Market Growth Analysis 2020 Recent Trends by Regions, Future Demand Status, Size and Share Value Analysis, Boosting Strategies, COVID-19 Impact by 2024

Vaccine Adjuvants Market 2020 by Top Countries Data with Share Analysis, Global Growth Trends, Market Size by Top Players, Geographical Segmentation Forecast to 2024

3D Computer Graphics Software Market Size Analysis 2020 with Business Boosting Technologies, Forthcoming Growth Rate, Top Regions, Key Players and Investments Opportunities Forecast to 2025

High Performance Plastics Market Size and Share Analysis 2020 Global Future Growth Rate, Industry Players, Developments Status, Trends Forecast to 2026 | Industry Research.co

https://neighborwebsj.com/

Link:
Platelet Rich Plasma Market: Applications, Business Trends by Size 2021: Growth Statistics and Key Players Insights by Types, and Development Analysis...

Coping With Cancer Treatment’s Effects on Skin – Curetoday.com

As she walked into Memorial Sloan Kettering Cancer Center, Erin Hazelton was struck by the appearance of the woman in front of her. Hazelton was at the New York, New York, cancer center to begin treatment for stage 2 invasive ductal carcinoma.

I walked into the center right after another woman, and when I heard her give her date of birth (to the receptionist), I realized that she was only a couple of years older than me, but she looked like she was my mothers age, recalled Hazelton, who received her diagnosis in 2018. When you (get a diagnosis) at age 37 (like I did), its scary. So much of my identity was tied up in how I looked. I was terrified.

Although many cancers are unseen, different types of treatment can lead to painful, visible side effects. After starting treatment, Hazelton experienced skin side effects including universal hair loss; facial wrinkles and loss of collagen; melasma (dark/discolored patches) on her face; dry skin; seeping wounds; scars; and radiation tattoos.

In addition to the regular side effects of chemotherapy, which can be devastating to quality of life, newer targeted therapies and immunotherapies have additional side effects of the skin that can be very frequent and very specific, says Dr. Nicole LeBoeuf, a dermatologist at Brigham and Womens Hospital and director of the skin toxicities program at Dana- Farber Cancer Institute in Boston, Massachusetts.

According to LeBoeuf, systemic cancer treatments can generally be grouped into three categories, and the types of side effects patients could experience will depend on the patients treatment regimen and cancer type.

The first category is cytotoxic, or classic, chemotherapy, which most commonly causes side effects including alopecia, or hair loss; painful rashes on the hands and feet; and general rashes elsewhere on the body that can lead to swelling, pain and itchiness.

Hazeltons initial regimen included Adriamycin (doxorubicin), a chemotherapy drug known as the red devil because of its harsh side effects, followed up with Taxol (paclitaxel). I lost all my hair eyelashes, eyebrows, everything and my skin looked like I had aged a good 15 to 20 years toward the end of it, Hazelton says. My cheeks had wrinkles because the collagen wasnt being renewed; I had melasma, which I hadnt expected, that was made worse by the sun.

She also experienced skin-related side effects from radiation and scars from her lumpectomy. My skin started slowly breaking down over the course of my radiation, and at the end of six weeks, I had seeping wounds, Hazelton says. My nipple looked like it was going to separate from my body.

The second category of treatment that can lead to skin side effects are targeted therapies, which are linked to the specific drug used for that patients treatment. The most commonly talked-about skin side effect of targeted therapy is called a papulopustular, or an acne-like, rash from EGFR inhibitors, or drugs that target the epidermal growth factor receptor mutation. This mutation is found in lung cancers, head and neck cancers, some colon cancers and, rarely, in breast cancer, LeBoeuf says. In fact, 85% of patients who are treated with drugs that target that particular genetic mutation will develop that rash.

Another common skin side effect from targeted therapies is hand-foot skin reaction, which causes painful calluses and blisters on pressure points. These blisters can occur from doing very normal activities, LeBoeuf says. Something as simple as going to the grocery store can make a patients feet look like theyve just run a marathon. Someone who works on a keyboard may experience painful blisters on their fingertips when they type.

Severe skin side effects such as these can prevent patients from resuming everyday activities and make them more likely to discontinue their cancer treatment, leading to a worse prognosis.

The third category of treatment leading to skin side effects is immunotherapy, a type of treatment that boosts the bodys natural defenses, or immune system, to fight the cancer. Immunotherapy is a beast because once you unleash the immune system, you can turn on any and all skin diseases that would happen outside the cancer setting. Anything that could possibly happen in the field of dermatology has been triggered by activating the immune system, LeBoeuf says. It is amazing and it is groundbreaking...but it can also lead to autoimmune disease in any organ.

The most common skin-related side effects of immunotherapies include psoriasis, with bumpy red patches covered in white scales; vitiligo, or whitish patches from lost pigment; and lichen planus, an autoimmune disease that can cause swelling and irritation of the skin, hair, nails and mucous membranes.

Sometimes the adverse immune events that are activated through immunotherapy persist after the treatment has ended. Our approach to these side effects is always to try to uncouple the toxicity from the effects of the drug on the cancer, then target the side effects as specifically as possible, LeBoeuf says. This leaves the rest of the immune system intact to fight the cancer.

Given the variety of possible side effects and the degree to which it may affect a given individual, it can be hard for patients to know which ones to expect and how to manage them if they arise during and after treatment.

Dr. Anisha Patel, an associate professor of dermatology at The University of Texas MD Anderson Cancer Center in Houston, recommends that patients follow good hair, skin and nail habits before starting treatment: Moisturize often, avoid perfumed products, and decrease the use of lacquer on your nails, she says.

Patients who have a history of skin conditions prior to their cancer diagnosis are more likely to see worsening during treatment. If you already have eczema, psoriasis, or acne, those things are more likely to be exaggerated, Patel says. If you have a preexisting skin condition, that should be taken care of before your therapy starts, as well.

During treatment, certain practices can help prevent the most common side effects. For example, wearing ice- cold gloves and socks and using scalp cooling treatments to restrict blood vessels reduces the chances of hair loss and hand-foot syndrome.

Patients should also take steps at home to minimize side effects. Wearing sunscreen, avoiding direct sun exposure and wearing a hat when outdoors can prevent photosensitivity side effects, Patel says.

To manage her symptoms, Hazelton applied organic shea butter daily and wore gloves and socks to bed to keep her skin as moisturized as possible. My nails were actually amazing during treatment because I was moisturizing them so religiously, she says. Whatever your skin can drink up during that time that is nontoxic, contains no preservatives and has no scents will help.

For patients who are undergoing targeted therapy or immunotherapy, dealing with side effects can be more complicated. In general, the newer cancer therapies (like immunotherapy) have very specific side effects, which may require specific treatment, Patel says. Patients have to go into it with the mindset that they will have some sort of side effect and ask their treatment team what to expect and what they can do to minimize it.

LeBoeuf recommends that patients seek the advice of a dermatologist, who can work with the medical oncologist to manage skin side effects. Whenever possible, if a specific dermatologic diagnosis can (be) made, then the most appropriate treatment can be instituted as quickly as possible, LeBoeuf says. If you treat the side effect specifically, based on dermatologic literature, then often, patients will recover and can continue their cancer treatment, as well.

Both Patel and LeBoeuf urge that the mental and emotional side effects of treatment-related skin conditions receive as much attention as the physical side effects. Often, patients are embarrassed or they feel like they shouldnt be concerned about a side effect that isnt life-threatening, LeBoeuf says. But the reality is, if a side effect affects your quality of life, increases your stress or changes your course of treatment, it can also affect your ability to fight the cancer. So be open, ask for help and advocate for referrals if you feel you arent getting the treatment you need. Maintaining skin health can also prevent secondary problems such as infections or ulcers and can minimize scarring.

Taking one day at a time helped Hazelton maintain a positive mindset. Thinking Am I going to burn during radiation? or Whats my scar going to look like? doesnt help you mentally. Just approach it as it comes, she says.

Patients might be surprised to learn that there is a silver lining to skin-related side effects: Skin side effects to some of the newer targeted and immune therapies is correlated to having a better tumor response, Patel says. It is correlated to the bodys immune system being revved up to fight the cancer.

Post treatment, patients should be advised about options to help restore the health of their skin, hair and nails. What happens after the treatment isnt talked about as much, Dr. Anthony Rossi, a dermatologist and surgeon specializing in skin cancer, lasers and cosmetic surgery at Memorial Sloan Kettering Cancer Center, says. Radiation can cause chronic changes in the skin; surgery, obviously, leaves a lot of scars, and high-dose steroids can leave stretch marks that last forever.

To combat these side effects, Rossi and his team at Memorial Sloan Kettering are working on what they call restorative oncodermatology, which, he says, aims to restore patients who go through cancer treatment and help them get back the form and function of their skin.

Through the use of treatments such as topical retinoids, topical skincare, chemical peels, lasers, botulinum neurotoxin (such as Botox) and platelet- rich plasma (or PRP) injections an experimental therapy that uses injections of the patients own blood platelets to prompt hair growth Rossi reports that many survivors are seeing life-changing results. There is definitely a cosmetic aspect that people want to improve... but these treatments help with skin functionality and overall quality of life, most importantly, he says.

Hazelton has received chemical peels and laser treatments to reduce her wrinkles and melasma, as well as used over- the-counter eyelash serums to help her hair grow back.

I thought my life was over when I got my diagnosis. I thought I would never look the same or feel the same ... but there are people out there to help you fix these physical things that remind you of your sickness, she says. A lot of people bounce back more than they expect they will. ... Your body really does recover; you just have to give it a chance.

See the original post here:
Coping With Cancer Treatment's Effects on Skin - Curetoday.com

AI project to power the future of stem cell manufacturing – TechCentral.ie

Stem cell images from DeepStain project

Valitacell, CeADAR receive 242,000 from Enterprise Ireland and EU

Print

Read More: AI artifical intelligence CeADAR stem cells Valitacell

A new project to improve stem cell manufacturing using artificial intelligence (AI) could have lasting impacts for the health sector.

The three-year project, entitled DeepStain: Deep Learning for Cell Image Analysis hopes toaccelerate an area of drug development which is at the root of many diseases.

DeepStain is part of a strategic partnership between Irish biotechnology company Valitacell and CeADAR, Irelands Centre for Applied Artificial Intelligence.

The project has received 242,000 funding from Enterprise Ireland and the EU under the Marie Skodowska-Curie Co-Fund Scheme, which is part of the Horizon 2020 Research and Innovation programme.

Stem cells have the potential to treat many conditions including cancer, arthritis, and Crohns disease. Monitoring stem cell quality involves a lot of slow and difficult laboratory work, meaning they can behard to manufacture.

The DeepStain project will use AIto quickly analyse images of stem cells to determine their quality and make stem cell manufacturing more efficient.

The core team is composed of Dr Ricardo Simon Carbajo (CeADAR), Dr Paul Dobson (Valitacell) and Dr PolatGkta(CeADAR & Valitacell), and builds on previous work and interdisciplinary expertise.

AI can massively help to improve the Biopharma value chain, said Dr Ricardo Simon Carbajo, head of innovation & development at CeADAR. In this project, we will be applying the latest techniques in Computer Vision to speed up the process of manufacturing stem cells. We are delighted to partner with Valitacell as they are truly innovating in this area and we can produce a real impact in society.

Working with CeADAR will help Valitacell leverage the power of Deep Learning to create better bioprocess analytical technologies to support stem cell therapy manufacturing, said Dr Paul Dobson, head of data at Valitacell. This will help translate stem cells from being a niche experimental therapy into a treatment available to patients worldwide.

TechCentral Reporters

Read More: AI artifical intelligence CeADAR stem cells Valitacell

View All Events

This course is designed to give you and your team all of the tools you need to lift architecture from a documentation process to a true business capability. All IT architects will benefit from the concepts presented in this course. 16 February, 63 CPD Points, Online

The Certified Data Protection Officer Programme has been designed to equip Data Protection Officers with the necessary skills and competencies to meet and maintain all aspects of data protection compliance. 2 March, 63 CPD Points, Online

Be confident that your organisations policies and procedures are legally compliant with data protection legislation by completing Irelands first certified data protection practitioner programme. 9 March, 31.5 CPD Points, Online

Published by Mediateam Ltd., Ireland technology media leader since 1976, 55 Spruce Ave, Sandyford, Dublin 18, A94 N125.

Privacy & Cookies Policy

Continued here:
AI project to power the future of stem cell manufacturing - TechCentral.ie

Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells – BioSpace

CAMBRIDGE, Mass. and NEW YORK, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Cytovia Therapeutics, Inc., a biopharmaceutical company developing allogeneic off-the-shelf gene-edited Natural Killer (NK) and Chimeric Antigen Receptor (CAR)-NK cells derived from induced pluripotent stem cells (iPSCs), and Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS) a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced today that they have entered into a strategic research and development collaboration to develop TALEN gene-edited iPSC NK and CAR-NK cells.

The financial terms of the partnership include up to $760 million of development, regulatory, and sales milestones from Cytovia to Cellectis for the first 5 TALEN gene-edited iPSC-derived NK products (partnership products). Cellectis will also receive single-digit royalty payments on the net sales of all partnered products commercialized by Cytovia. Cellectis will receive an equity stake of $15 million in Cytovia stock or an upfront cash payment of $15 million if certain conditions are not met by December 31, 2021, as well as an option to invest in future financing rounds.

We are excited to collaborate with Cellectis, a gene-editing pioneer and leader in the development of gene-edited allogeneic cancer therapies, to further accelerate Cytovias NK cell programs, said Dr. Daniel Teper, Chairman & CEO of Cytovia Therapeutics. Cellectis has a deep understanding and proven expertise in gene-edited cell therapies, and their gene editing technology, TALEN, will yield NK and CAR-NK treatments with improved potency, persistence, and safety for a variety of cancers, including solid tumors. We look forward to leveraging Cellectis insights and experience to help move Cytovias CAR-NKs into clinical trials by 2022.

Cellectis will develop custom TALEN, which Cytovia will use to edit iPSCs. Cytovia will be responsible for the differentiation and expansion of the gene-edited iPSC master cell bank into NK cells and will conduct the pre-clinical evaluation, clinical development, and commercialization of the mutually-agreed-upon selected therapeutic candidates. Cellectis is granting Cytovia a worldwide license to its TALEN gene-editing technology, enabling Cytovia to modify NK cells addressing multiple gene targets for therapeutic use in several cancer indications.

We are thrilled to partner with Cytovia, a pioneer in the development of NK cells derived from iPSCs, said Dr. Andr Choulika, CEO of Cellectis. We are looking forward to this collaboration and the opportunity to further expand the potency of our proprietary TALEN gene-editing technology to iPSCs and CAR-NKs. Down the road, this collaboration should allow for NK cell therapies to be made available to cancer patients, which is very much in line with Cellectis mission to provide life-saving product candidates to address unmet patient needs in this field.

About Cellectis Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.

As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).

Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit http://www.cellectis.com.

Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

TALEN is a registered trademark owned by Cellectis.

About Cytovia Therapeutics Cytovia Therapeutics Inc. is a biotechnology company that aims to accelerate patient access to transformational immunotherapies, addressing several of the most challenging unmet medical needs in cancer. Cytovia focuses on Natural Killer (NK) cell biology and is leveraging multiple advanced patented technologies, including an induced pluripotent stem cell (iPSC) platform for CAR (Chimeric Antigen Receptors) NK cell therapy, next-generation precision gene-editing to enhance targeting of NK cells, and NK engager multi-functional antibodies. Our initial product portfolio focuses on both hematological malignancies such as multiple myeloma and solid tumors including hepatocellular carcinoma and glioblastoma. The company is establishing R&D and GMP manufacturing operations in the greater Boston area and partners with the University of California San Francisco (UCSF), the New York Stem Cell Foundation (NYSCF), the Hebrew University of Jerusalem, INSERM, and CytoImmune Therapeutics. Learn more at http://www.cytoviatx.com and follow Cytovia Therapeutics on Social Media (Facebook, LinkedIn, Twitter, and Youtube).

About Gene-Edited, iPSC-derived NK Cells Chimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR-NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD). In addition, CAR-NKs are naturally allogeneic, available off-the-shelf and may be able to be administered on an outpatient basis. Recent innovative developments with the induced pluripotent stem cell (iPSC)-derived CAR-NKs, an innovative technology, allow large quantities of true off-the-shelf, homogeneous genetically modified CAR NK cells to be produced from a gene-edited iPSC master cell bank, and thus hold promise to expand access to cell therapy for many patients.

For further information, please contact:

Cellectis Media contacts: Margaret Gandolfo, Communications Manager, 646-628-0300, margaret.gandolfo@cellectis.com Conor McGoldrick, Zeno Group, Assistant Account Executive, 914-355-0927, Conor.Mcgoldrick@zenogroup.com

Cellectis IR contact: Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, simon.harnest@cellectis.com

Cytovia Investor Relations contact: Anna Baran-Djokovic VP of Investor Relations 646-355-1787 anna@cytoviatx.com

Cytovia Media contact: Chris Maggos LifeSci Advisors +41 79 367 6254 chris@lifesciadvisors.com

Disclaimer

This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as at this time, believe, expected, forward looking, promising and will, or the negative of these and similar expressions. These forward-looking statements, are based on our managements current expectations and assumptions and on information currently available to management. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2019 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

PDF available at: http://ml.globenewswire.com/Resource/Download/c6bbee7d-f56e-400c-a6a4-28586a9e4851

Read more:
Cytovia Therapeutics and Cellectis Partner to Develop TALEN Gene-Edited iPSC-Derived Natural Killer Cells - BioSpace

Induced Pluripotent Stem Cells Market Growth Opportunities, Analysis and Forecasts Report 2020-2026 with key players position (Fujifilm Holding…

The Induced Pluripotent Stem Cells Market grew in 2019, as compared to 2018, according to our report, Induced Pluripotent Stem Cells Market is likely to have subdued growth in 2020 due to weak demand on account of reduced industry spending post Covid-19 outbreak. Further, Induced Pluripotent Stem Cells Market will begin picking up momentum gradually from 2021 onwards and grow at a healthy CAGR between 2021-2025.

Deep analysis about Induced Pluripotent Stem Cells Market status (2016-2019), competition pattern, advantages and disadvantages of products, industry development trends (2019-2025), regional industrial layout characteristics and macroeconomic policies, industrial policy has also been included. From raw materials to downstream buyers of this industry have been analysed scientifically. This report will help you to establish comprehensive overview of the Induced Pluripotent Stem Cells Market

Get a Sample Copy of the Report at: https://i2iresearch.com/download-sample/?id=8913

The Induced Pluripotent Stem Cells Market is analysed based on product types, major applications and key players

Key product type: Hepatocytes Fibroblasts Keratinocytes Amniotic Cells Others

Key applications: Academic Research Drug Development And Discovery Toxicity Screening Regenerative Medicine

Key players or companies covered are: Fujifilm Holding Corporation Astellas Pharma Fate Therapeutics Bristol-Myers Squibb Company ViaCyte Celgene Corporation Aastrom Biosciences Acelity Holdings StemCells Japan Tissue Engineering Organogenesis

The report provides analysis & data at a regional level (North America, Europe, Asia Pacific, Middle East & Africa , Rest of the world) & Country level (13 key countries The U.S, Canada, Germany, France, UK, Italy, China, Japan, India, Middle East, Africa, South America)

Inquire or share your questions, if any: https://i2iresearch.com/need-customization/?id=8913

Key questions answered in the report: 1. What is the current size of the Induced Pluripotent Stem Cells Market, at a global, regional & country level? 2. How is the market segmented, who are the key end user segments? 3. What are the key drivers, challenges & trends that is likely to impact businesses in the Induced Pluripotent Stem Cells Market? 4. What is the likely market forecast & how will be Induced Pluripotent Stem Cells Market impacted? 5. What is the competitive landscape, who are the key players? 6. What are some of the recent M&A, PE / VC deals that have happened in the Induced Pluripotent Stem Cells Market?

The report also analysis the impact of COVID 19 based on a scenario-based modelling. This provides a clear view of how has COVID impacted the growth cycle & when is the likely recovery of the industry is expected to pre-covid levels.

Contact us: i2iResearch info to intelligence Locational Office: *India, *United States, *Germany Email: [emailprotected] Toll-free: +1-800-419-8865 | Phone: +91 98801 53667Induced Pluripotent Stem Cells, Induced Pluripotent Stem Cells Market, Induced Pluripotent Stem Cells Market Size, Induced Pluripotent Stem Cells Market Growth, Induced Pluripotent Stem Cells Market forecast, Induced Pluripotent Stem Cells Industry, Induced Pluripotent Stem Cells Market Overview, Induced Pluripotent Stem Cells Market Share, Induced Pluripotent Stem Cells Trends, Induced Pluripotent Stem Cells Market Analysis, Induced Pluripotent Stem Cells Market Revenue, North America Induced Pluripotent Stem Cells Market, Europe Induced Pluripotent Stem Cells Market, Asia Pacific Induced Pluripotent Stem Cells Market, Middle East & Africa Induced Pluripotent Stem Cells Market

https://neighborwebsj.com/

Excerpt from:
Induced Pluripotent Stem Cells Market Growth Opportunities, Analysis and Forecasts Report 2020-2026 with key players position (Fujifilm Holding...

Can we freeze them? Yes we can, says Nkarta – Vantage

Paul Hastings, chief executive of Nkarta, is not shy about his companys achievement. We have mastered cryopreservation, he tells Evaluate Vantage.

And with that the company might have solved the biggest problem to have held back development of NK cell therapeutics: normally the cells cannot be frozen without risking changing their phenotype. Nkarta also reckons to have cracked another problem, transducing NK cells with a retrovirus, and its optimism matches the market mood of resurgent enthusiasm for these therapies.

That enthusiasm for NK cells took off at last years Ash meeting, and Nkarta, along with Gamida Cell, Fate Therapeutics and Nantkwest, celebrated surging stock prices. Remarkably, Nkarta presented no clinical data at the conference, though it has since started trials of its first Car-NK therapy, NKX101, targeting NKG2D ligands.

What do we want?

One of the things we defined right up front was what we wanted from a product, Mr Hastings says. Until we got that we werent going to try and move these things into the clinic.

For Nkarta a product must be off the shelf and cryopreserved though just how this is achieved is a proprietary secret and it must come in a vial, not a bag, so it can be multiple-dosed easily. The aim is to ship Car-NK cells just like an antibody directly to a doctor.

Thus affordability, a thorny issue for cell therapies, is at the core of Nkartas thinking. Mr Hastings reckons cost of manufacturing can be limited to $2,000 per vial of a billion NK cells; and, as each dosing cycle comprises three lots of 100 million cells, each vial could give up to three cycles.

As for supply, Nkarta sources NK cells from healthy donors, in contrast to Fate, which uses induced pluripotent stem cells (iPSCs). Mr Hastings says each healthy donor can yield 500 doses, and manufacturing, including standard viral transduction, takes 14 days, with the inclusion of membrane-bound IL-15 improving persistence and reducing exhaustion, ensuring that cells are maximally potent when delivered.

TheiPSC approach is seen as more advanced, but iscomplex asdesired characteristics need to be engineered in. Mr Hastings says with donor-derived cells you start with a large number of cells, and theyre actually NK cells, though he does not rule out looking at iPSCs in future.

Were all placing bets, and this is our bet, adds James Trager, Nkartas chief scientific officer. And he denies that donor-derived cells lack flexibility, saying the donor pool is very diverse: There are a fair number of donors walking around who have NK cells with pretty exceptional properties.

For now, however, Nkarta is not looking at donors with NK cells expressing high-affinity CD16; Fate, for instance, engineers this into most of its projects to improve antibody-dependent killing.

Clinical data

Investors do not have long to wait for the first evidence of NKX101s clinical activity. Mr Hastings says Nkarta expects interim results from a handful of patients at a medical meeting not by press release towards the end of 2021.

And an IND filing for the groups second asset, a CD19-targeting Car-NK coded NKX019, is due in the current quarter. This gives Nkartas pipeline a mix of proven (CD19) and high-risk (NKG2D ligands) approaches, and final proof-of-concept data for both are due in the first half of 2023; current cash, meanwhile, takes Nkarta to the second half of that year.

On a design level both therapies differ from current Car-T approaches in using as the co-stimulatory domain not 4-1BB or CD28 but Ox40, which Mr Trager says gives NK cells the best serial killing activity.

Even though the CD19 space is extremely crowded, unlike many other cell therapy players Nkarta is not using a CD19 approach just to test its tech. We absolutely believe that a CD19 programme thats allogeneic, cryopreserved in a vial is going to be very competitive, stresses Mr Hastings.

And the groups next project will target solid tumours, but for now remains under wraps. The way well disclose targets is when we have a clinical candidate, says the chief exec.

See original here:
Can we freeze them? Yes we can, says Nkarta - Vantage

Global Induced Pluripotent Market Positive Outlook, Revenue Generation & Leading Manufacturers, Forecast 2026||CELGENE CORPORATION; Astellas…

A consistent statistical surveying report like this Induced Pluripotent report stretches out your reach to the achievement in your business. All the information and measurement remembered for the report is supported up by notable investigation devices which incorporate SWOT examination and Porters Five Forces investigation. Statistical surveying contemplates did in this report are chivalrous which help organizations to take better choices and create predominant methodologies about creation, advertising, deals and advancement. Market definition, market division, key improvements in the market, serious investigation and examination approach are the significant section of this Induced Pluripotent market report which are again explained accurately and explicitly.

Induced Pluripotent statistical surveying report has been formed with most up-to-date insight and examination to give greatest advantages to the healthcare business. The Induced Pluripotent market report features the worldwide key makers to characterize, depict and break down the market rivalry scene through SWOT investigation. A variety of goals of the showcasing research has been considered to produce this best statistical surveying report. The market information introduced in the report assists with perceiving diverse market openings present globally. Serious investigation acted in this Induced Pluripotent report makes you mindful about the moves of the vital participants in the market, for example, new item dispatches, extensions, arrangements, joint ventures, associations, and acquisitions.

Few of the major competitors currently working in the induced pluripotent market areBristol-Myers Squibb Company; CELGENE CORPORATION; Astellas Pharma Inc.; Thermo Fisher Scientific; Cell Applications, Inc.; Axol Bioscience Ltd.; Organogenesis Holdings; Merck KGaA; FUJIFILM Holdings Corporation; Fate Therapeutics; KCI Licensing, Inc.; Japan Tissue Engineering Co., Ltd.; Vericel; ViaCyte, Inc.; STEMCELL Technologies Inc.; Horizon Discovery Group plc; Lonza; Takara Bio Inc.; Promega Corporation and QIAGEN.

Objective of the Report

Market Drivers

Market Restraints

Get Full Table Of content @ https://www.databridgemarketresearch.com/toc/?dbmr=global-induced-pluripotent-market

Key Developments in the Market:

Segmentation: Global Induced Pluripotent Market

By Product Category

By Cell Type

By Application

By End-User

By Geography

Inquiry For Customize Report With Discount at :https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-induced-pluripotent-market

Potentials held by the report

AboutData Bridge Market Research

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune. We ponder into the heterogeneous markets in accord with our clients needs and scoop out the best possible solutions and detailed information about the market trends. Data Bridge delve into the markets across Asia, North America, South America, Africa to name few.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact: Data Bridge Market Research Tel: +1-888-387-2818 Email:Corporatesales@databridgemarketresearch.com

Read this article:
Global Induced Pluripotent Market Positive Outlook, Revenue Generation & Leading Manufacturers, Forecast 2026||CELGENE CORPORATION; Astellas...

Induced Pluripotent Stem Cells Market Growth, Competitive Landscape, Research Methodology, Business Opportunities, Statistics and Industry Analysis…

The latest report is the most recent study that offers 360 coverage of the Induced Pluripotent Stem Cells industry that has been facing the brunt of the adverse economic impact of the COVID-19 outbreak since the beginning of this year.

Top Companies Profiled in this Report are:

Thermo Fisher Scientific, Allele Biotechnology and Pharmaceuticals Inc., ABM (Applied Biological Materials Inc.), Addgene, Axol Bioscience, Cell Signaling Technology, Bluerock Therapeutics, Alstem LLC, Applied Stemcell Inc., ATCC, Creative Bioarray, Bristol-Myers Squibb, Bio-Techne, Reprocell Group Co., Primorigen Biosciences, ID Pharma Co. Ltd., Megakaryon Corp., FUJIFILM Cellular Dynamics, Inc., Waisman Biomanufacturing, Roslin Cell Sciences, Opsis Therapeutics, Corning Life Sciences, Fate Therapeutics, Genecopoeia, Gentarget Inc., Viacyte Inc., Ncardia, Invivogen, Lonza Group Ltd., Plasticell Ltd., Stemcell Technologies, Newcells Biotech, Orig3N Inc., Peprotech, Promega Corp., Promocell Gmbh, Qiagen N.V., System Biosciences Inc., Reprocell Inc., Sciencell Research Laboratories, MilliporeSigma, and Takara Bio Usa Inc.

Overview of the Induced Pluripotent Stem Cells report:

The Induced Pluripotent Stem Cells market has been broadly segmented to aid readers in gaining a more in-depth understanding of different facets and attributes of the market. The market scope for the new entrants and established companies has been assessed using various analytical tools, including the SWOT analysis, investment assessment, and Porters Five Forces analysis. Furthermore, into the study, the authors of the report have evaluated the financial standing of leading companies operating in the industry. They have provided crucial information on gross profits, revenue shares, sales volume, manufacturing costs, individual growth rate, and numerous other financial ratios of these competitors.

Click to get Discount on this Induced Pluripotent Stem Cells Market [emailprotected] https://www.reportsanddata.com/discount-enquiry-form/3551

Segmentation Analysis

The report gives an extensive analysis of various segments of the market by studying the product range, applications, major regions, and leading companies in the industry. Additionally, the report also dedicates an individual section to give a detailed analysis of the manufacturing process, which includes information collected through both primary and secondary sources of data collection. The primary source of data collection contains interviews of industry experts who offer accurate insights into the future market scenario.

Derived Cell Type Outlook (Revenue in USD Million; 20172027)

Application Outlook (Revenue in USD Million; 20172027)

End-User Outlook (Revenue in USD Million; 20172027)

Induced Pluripotent Stem Cellsmarket segmentation by geographical regions, the report has analysed the following regions-

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Download Summary[Free Extract]@ https://www.reportsanddata.com/sample-enquiry-form/3551

The Induced Pluripotent Stem Cells Market Research/Analysis Report addresses the following questions:

WhichManufacturing Technologiesare prevalent in the production of Induced Pluripotent Stem Cells? What are the Recent Developmentsrelating to that technology? WhichTrendsare responsible for these developments?

Who are the leading vendors in the GlobalInduced Pluripotent Stem Cells Market? What are their individual market standing and contact information?

What is the current industrial scenario of the Global Induced Pluripotent Stem Cells Market? What were the Value, Volume, Production Capacity, Cost, and Profit Margin of the overall market?

What is the outcome of the competitive analysis on the Induced Pluripotent Stem Cells Market both in terms of companies and regions? What is the market assessment for the Induced Pluripotent Stem Cells Market as per the market segmented into types and applications?

Thank you for reading our report. Customization of the report is available as per client requirements. Kindly get in touch with us to know more about the report.

Explore our related report :

Hemostasis Analyzers Market Growth

Surgical Instruments Market Share

Tele-Intensive Care Unit (ICU) Market Size

Dimethylformamide (DMF) Market Trends

About Reports and Data

Reports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help clients make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.

Get Insights into Induced Pluripotent Stem Cells Market [emailprotected] https://www.reportsanddata.com/report-detail/induced-pluripotent-stem-cells-market

Contact Us:

John W

Head of Business Development

Direct Line: +1-212-710-1370

Explore our related report from different Publications:

Cosmetic Chemicals Industry Growth Rate

Cosmetic Chemicals Industry Revenues

Cosmetic Chemicals Market Projections

Cosmetic Chemicals Market Revenue

Cosmetic Chemicals Industry Sales

Cosmetic Chemicals Sales Statistics

Cosmetic Chemicals Industry Annual Sales

Cosmetic Chemicals Industry Growth Rate

Cosmetic Chemicals Industry Revenues

Cosmetic Chemicals Market Projections

Cosmetic Chemicals Industry Growth Rate

Cosmetic Chemicals Industry Revenues

Cosmetic Chemicals Market Projections

Cosmetic Chemicals Market Revenue

Cosmetic Chemicals Industry Sales

Continued here:
Induced Pluripotent Stem Cells Market Growth, Competitive Landscape, Research Methodology, Business Opportunities, Statistics and Industry Analysis...

Winter Weather Impacting Blood and Platelet Donations – Milwaukee Community Journal

Versiti Blood Center of Wisconsin calling on donors to help as supplies drop;

blood types O-negative, O-positive most needed

Milwaukee Feb. 16, 2021 With winter storm warnings and advisories in place across much of the Midwest, Versiti Blood Centers is grappling with low and quickly dwindling supplies of blood and platelet donations.

The unrelenting winter weather is taking its toll on the blood supply across the Midwest, said Dr. Dan Waxman, vice president of transfusion medicine and senior medical director at Versiti. Supplies of some blood types, including O-negative and O-positive, are reaching critically low levels, with less than a days supply of life-saving blood on shelves to supply Versitis hospital partners across Wisconsin, Indiana, Illinois, Michigan and Ohio. We simply do not have the three-day supply of blood that we need.

The winter weather advisories and warnings are adding to the ongoing blood collection challenges that centers have been facing during COVID due to remote work and schooling. In the past year, Versiti has experienced a 47% decrease in mobile drive collections at business and schools.

Platelets which are used to help cancer patients, trauma survivors and premature babies are only viable for five to seven days outside the body, creating a constant and ongoing need for donations. Like blood, platelets cant be manufactured, so Versiti needs volunteer donors to roll up their sleeves.

We are asking the community to step forward and help, said Dr. Waxman. Unfortunately, we cant wait a week until a cold snap subsides to provide these life-saving gifts. For these patients who rely on us, they need our help today, regardless of the weather forecast.

O-negative and O-positive blood donors are most needed now. O-negative and O-positive blood is the universal blood type, meaning donations can be transfused to all patients, including trauma victims, cancer patients and those undergoing surgery.

Badgers are needed to extend the generous gift of life to neighbors who need help and to donate blood at a Versiti Blood Center of Wisconsin donor center nearest them:

Wisconsin residents can also make an appointment to donate at a local community blood drive in their area. Times, dates and locations of upcoming local drives can be found online https://donate.wisconsin.versiti.org. Interested donors should click the Schedule to Donate tab to find the nearest drive to them.

To help ensure donor safety, everyone entering Versiti facilities must wear a mask and have their temperature taken. All Versiti donation locations are practicing social distancing and closely adhering to CDC recommendations and cleaning protocols.

Donating blood takes about an hour with the actual donation taking 10-15 minutes. Anyone age 17 or older in good health who meets eligibility requirements is encouraged to give. Parental consent is required for donors age 16 to donate blood. Donors should bring a photo ID that includes their birth date.

Appointments are encouraged at any of Versitis Wisconsin donor centers or at any local community blood drive. Walk-ins are always welcome. To schedule an appointment to donate blood, call 1-877-BE-A-HERO or visit Versiti online at versiti.org/Wisconsin.

# # #

About Versiti Blood Center of Wisconsin

Versiti Blood Center of Wisconsin is a not-for-profit organization headquartered in Milwaukee that specializes in blood services, esoteric diagnostic testing, organ, tissue and stem cell

donation, medical services and leading-edge research. We advance patient care by delivering life-saving products and services. For more information, visit versiti.org/Wisconsin.

Here is the original post:
Winter Weather Impacting Blood and Platelet Donations - Milwaukee Community Journal